References
- Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–e33. doi:10.1016/S2214-109X(14)70227-X.
- American College of Obstetricians and Gynecologists. Hypertension in Pregnancy. Report of the american college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–29. doi:10.1097/01.AOG.0000437382.03963.88.
- Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–94. doi:10.1126/science.1111726.
- McClure JH, Cooper GM, Clutton BTH. Centre for Maternal and Child Enquiries. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006-8: a review. Br J Anaesth. 2011;107:127–32. doi:10.1093/bja/aer192.
- Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating anti angiogenic factors in preeclampsia. New Eng J Med. 2006;355(10):992–1005. doi:10.1056/NEJMoa055352.
- Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens. 2015;24(2):131–38. doi:10.1097/MNH.0000000000000105.
- Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14(3):528–52. doi:10.1111/j.1582-4934.2009.00941.x.
- Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy. 2007;26:447–62. doi:10.1080/10641950701521742.
- Thangaratinam S, Gallos ID, Meah N, Usman S, Ismail KM, Khan KS, et al. How accurate are maternal symptoms in predictingimpending complications in woman with preeclampsia? A systematic review and metaanalysis. Acta Obstet Gynecol Scand. 2011;90(6):564–73. doi:10.1111/j.1600-0412.2011.01111.x.
- Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med. 2011;24:1187–207. doi:10.3109/14767058.2011.589932.
- Shanghai S 2017. Shanghai Sunred Biological Technology Co., Ltd . [ Accessed]. http://www.sunredbio.com/esearchlist.asp.
- Andersen LB, Frederiksen-Moller B, Work Havelund K, Dechend R, Jorgensen JS, Jensen BL, et al. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. J Am Soc Hypertens. 2015;9(2):86–96. doi:10.1016/j.jash.2014.11.008.
- Karampas GA, Eleftheriades MI, Panoulis KC, Rizou MD, Haliassos AD, Metallinou DK, et al. Prediction of pre-eclampsia combining NGAL and other biochemical markers with Doppler in the first and/or second trimester of pregnancy. Pilot Study Eur J Obstet Gynecol Reprod Biol. 2016;205:153–57. doi:10.1016/j.ejogrb.2016.08.034.
- Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive Value of the sFlt-1: plGFRatio in Women with Suspected Preeclampsia. N Eng J Med. 2016;374:13–22. doi:10.1056/NEJMoa1414838.
- Tang P, Xu J, Xie BJ, Wang QM. Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia. Hypertens Pregnancy. 2017;36:48–52. doi:10.1080/10641955.2016.1237642.
- Mckeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191(4):1240–46. doi:10.1016/j.ajog.2004.03.004.
- Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Eng J Med. 2004;350:672–83. doi:10.1056/NEJMoa031884.
- Vaisbuch E, Whitty JE, Hassan SS, Romero R, Kusanovic JP, Cotton DB, et al. Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol. 2011;204:e151–e159. doi:10.1016/j.ajog.2010.08.049.
- Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, et al. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy. 2016;35:295–305. doi:10.3109/10641955.2016.1141214.
- Turpin CA, Sakyi SA, Owiredu WK, Ephraim RK, Anto EO. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia. BMC Pregnancy Childbirth. 2015;15:189. doi:10.1186/s12884-015-0624-y.
- Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109:1316–24. doi:10.1097/01.AOG.0000265804.09161.0d.
- Masoura S, Kalogiannidis I, Makedou K, Theodoridis T, Koiou K, Gerou S, et al. Biomarkers of endothelial dysfunction in preeclampsia and neonatal morbidity: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2014;175:119–23. doi:10.1016/j.ejogrb.2014.01.012.
- March MI, Geahchan C, Wenger J, Raghuraman N, Berg A, Haddow H, et al. Circulating angiogenic factors and the risk of adverse outcomes among Haitian women with preeclampsia. PLoS One. 2015;10:e0126815. doi:10.1371/journal.pone.0126815.